About the bill
H.R. 5605 establishes a four-year demonstration program to increase access to treatment for opioid use disorder. The demonstration would provide incentive payments and funding for care management services based on criteria such as patient engagement, use of evidence-based treatments, and treatment length and intensity. Under the bill, the Secretary of Health and Human Services would be directed to encourage other payers to coordinate payments for opioid use disorder treatments and to evaluate the extent to which the demonstration reduces hospitalizations, increases the use of medication-assisted treatments, and improves the ...
Sponsor and status
- Introduced:
Apr 24, 2018
- Status:
-
Enacted Via Other Measures
Provisions of this bill were incorporated into other bills which were enacted, so there will not likely be further activity on this bill.
This bill was incorporated into:
H.R. 6: SUPPORT for Patients and Communities ActEnacted — Signed by the President on Oct 24, 2018. (compare text) - Prognosis:
-
41% chance of being enacted according to Skopos Labs (details)
What stakeholders are saying
History
|
Apr 24, 2018
|
|
Introduced
Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber. |
|
May 17, 2018
|
|
Ordered Reported
A committee has voted to issue a report to the full chamber recommending that the bill be considered further. Only about 1 in 4 bills are reported out of committee. |
|
Jun 12, 2018
|
|
Reported by House Committee on Energy and Commerce
A committee issued a report on the bill, which often provides helpful explanatory background on the issue addressed by the bill and the bill's intentions. |
|
Jun 19, 2018
|
|
Passed House (Senate next)
The bill was passed in a vote in the House. It goes to the Senate next. The vote was by voice vote so no record of individual votes was made. |
|
Jun 22, 2018
|
|
Final Bill —
Passed House (Senate next)
This activity took place on a related bill, H.R. 6, possibly in lieu of similar activity on H.R. 5605. |
|
Sep 17, 2018
|
|
Final Bill —
Passed Senate with Changes (back to House)
This activity took place on a related bill, H.R. 6, possibly in lieu of similar activity on H.R. 5605. |
|
Oct 3, 2018
|
|
Final Bill —
Senate Agreed to Changes
This activity took place on a related bill, H.R. 6, possibly in lieu of similar activity on H.R. 5605. |
|
Oct 24, 2018
|
|
Final Bill —
Enacted — Signed by the President
This activity took place on a related bill, H.R. 6, possibly in lieu of similar activity on H.R. 5605. |
H.R. 5605 is a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
“H.R. 5605 — 115th Congress: Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act.” www.GovTrack.us. 2018. December 13, 2018 <https://www.govtrack.us/congress/bills/115/hr5605>
- show another citation format:
- APA
- Blue Book
- Wikipedia Template
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.
